CTI(SZ:300012) Ge Long Hui·2026-01-29 07:02Core Viewpoint - The company is actively engaged in research and preparedness related to the recent spread of new viruses, emphasizing its commitment to public health safety and social responsibility [1] Group 1: Company Initiatives - The company's medical laboratory is monitoring global public health dynamics, including in India, and has initiated technical research and preparedness efforts in response to recent virus transmission [1] - The laboratory is advancing the development and validation of testing methods in accordance with relevant technical specifications and is following the application process for compliance qualifications [1] - The company is committed to maintaining communication with relevant departments to ensure technical readiness for public health emergencies [1] Group 2: Certifications and Capabilities - Suzhou Huace Biological, a key platform in the company's pharmaceutical services sector for non-clinical research, has received GLP certification from the National Medical Products Administration (NMPA) and has successfully passed multiple reviews [1] - The platform has also obtained full accreditation from AAALAC International, enabling it to conduct research related to the efficacy, safety evaluation, toxicokinetics, and bioanalysis of viruses and antiviral drugs [1] Group 3: Market Focus and Development - The company is attentive to changes in the demand for infectious disease prevention and antiviral drug research, providing non-clinical research technical support to domestic and internationally positioned clients under compliance [1] - Non-clinical research and bioanalysis services are crucial components of the company's pharmaceutical services sector, which has maintained steady growth driven by the demand for innovative drug development [1] - The company aims to strengthen its technical capabilities to promote the long-term stable development of its pharmaceutical services business [1]